Aurobindo Pharma Ltd.

Aurobindo Pharma Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, prompting a downgrade in its Mojo Grade from Buy to Hold. This change reflects a transition from fair to expensive valuation levels, raising questions about the stock's price attractiveness amid evolving market dynamics and peer comparisons.

Aurobindo Pharma Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 25 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 August 2026, providing investors with an up-to-date view of its performance and prospects.

Aurobindo Pharma Ltd. has demonstrated a notable shift in technical momentum, moving from a mildly bullish stance to a more confident bullish trend across multiple timeframes. This transition is underscored by positive signals from key technical indicators such as MACD, Bollinger Bands, and moving averages, suggesting renewed investor interest and potential upside in the pharmaceutical sector amid broader market fluctuations.

Aurobindo Pharma Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a subtle shift in its technical momentum, moving from a bullish to a mildly bullish stance. Despite a modest day decline of 0.59%, the stock’s technical indicators present a complex picture, with some signals suggesting sustained strength while others hint at caution. This nuanced technical landscape warrants close attention from investors seeking to navigate the stock’s evolving trend dynamics.

Aurobindo Pharma Ltd. has witnessed a notable 13.6% surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite this, the stock underperformed its sector and broader indices, reflecting a complex interplay of volume patterns and price movements that investors must carefully analyse.

Aurobindo Pharma Ltd. has witnessed a notable 13.4% increase in open interest in its derivatives segment, signalling heightened market activity despite the stock’s recent underperformance. This surge in open interest, coupled with volume patterns and price movements, suggests evolving market positioning and potential directional bets among traders.

Aurobindo Pharma Ltd. has witnessed a notable 10.9% increase in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a 2.94% decline in the stock price on 22 Jul 2026, the surge in open interest and volume patterns suggest evolving directional bets amid broader sector and market pressures.

Aurobindo Pharma Ltd. has witnessed a notable 10.46% increase in open interest in its derivatives segment, signalling heightened market activity despite the stock’s recent underperformance. This surge in open interest, coupled with volume patterns and price movements, offers insights into evolving market positioning and potential directional bets by investors in the pharmaceuticals and biotechnology sector.

Aurobindo Pharma Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 25 May 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 22 July 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Aurobindo Pharma Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 25 May 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 11 July 2026, providing investors with the most recent insights into the company’s performance and outlook.

Aurobindo Pharma Ltd. has witnessed a notable surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. The pharmaceutical giant’s stock hit a new 52-week high of Rs 1,636.8 on 3 July 2026, supported by robust volume and a strong uptick in futures and options activity, reflecting growing bullish sentiment despite a recent downgrade in its Mojo Grade to Hold.

Aurobindo Pharma Ltd. has witnessed a notable surge in open interest in its derivatives segment, signalling increased market participation and potential directional bets. The stock’s recent price action, coupled with rising volumes and a fresh 52-week high, underscores a bullish sentiment among traders despite a recent downgrade in its mojo grade.

Surging past its previous peaks, Aurobindo Pharma Ltd. touched a fresh 52-week high of Rs 1610 on 3 Jul 2026, marking a significant milestone in its price momentum. This advance comes amid a backdrop of strong technical signals and sustained outperformance relative to its sector and the broader market.

With a decisive surge to Rs 1588.85 on 1 Jul 2026, Aurobindo Pharma Ltd. has reached a fresh 52-week high, extending its impressive 37.87% gain over the past year against the Sensex’s decline of 8.35%. This milestone reflects a strong alignment of technical indicators and sustained price momentum that has propelled the stock well above its key moving averages.

Aurobindo Pharma Ltd. has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and potential directional bets. The pharmaceutical mid-cap stock outperformed its sector peers, hitting a fresh 52-week high of Rs 1,588, supported by robust volume and rising investor participation.

Aurobindo Pharma Ltd. has witnessed a significant surge in open interest (OI) in its derivatives segment, signalling heightened market activity and potential directional bets. The pharmaceutical mid-cap stock hit a fresh 52-week high of Rs 1,588 on 30 Jun 2026, outperforming its sector and reflecting robust investor participation amid improving technical and fundamental indicators.